Tidemark’s Cue Biopharma CUE Stock Holding History

Tidemark’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58K	Hold	50	–	–	﹤0.01%	712
2026 Q1	$345	Hold	50	–	–	﹤0.01%	810
2025 Q4	$458	Hold	50	–	–	﹤0.01%	627
2025 Q3	$1.08K	Hold	50	–	–	﹤0.01%	632
2025 Q2	$1.02K	Hold	50	–	–	﹤0.01%	643
2025 Q1	$1.37K	Buy	+50	New	+$1.86K	﹤0.01%	640

Other funds holding CUE

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Tidemark's CUE Position: Q2 2026 in Review

Tidemark held its Cue Biopharma (CUE) position steady in Q2 2026 at 50 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #712.

Tidemark first reported a position in CUE in Q1 2025 and has held it in 6 quarters since. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

Tidemark held 50 shares of Cue Biopharma worth $1.58K as of Q2 2026.
Tidemark left its Cue Biopharma share count unchanged in Q2 2026.
Cue Biopharma made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #712 holding.
Tidemark first reported a position in Cue Biopharma in Q1 2025 and has held it in 6 quarters since.
49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.